Question explored with the scientific record
Do the alleged benefits of statins outweigh the side effects?
The short version: statins reduce heart attacks and strokes in people who already have heart disease, but the benefit for healthy people is smaller than most patients are told, and the side effects are real and undercounted.
The evidence here is a stack of industry-funded trials and meta-analyses that mostly compare statins to placebo in high-risk patients. The 2013 Cochrane review of primary prevention found that for every 100 people without heart disease who take a statin for about 4 years, roughly 1 fewer dies and 1 fewer has a stroke, while 1 in 89 gets a new diabetes diagnosis [21, 36]. The 2010 Lancet meta-analysis put the diabetes risk at about 1 extra case per 255 patients treated [36]. A 2017 meta-analysis of observational studies found a 44% higher risk of new diabetes with statins overall, and higher still with rosuvastatin and atorvastatin [32]. The muscle symptoms are harder to count because the trials use a nocebo-prone design: in the SAMSON study, 90% of symptom burden came from the placebo, not the drug [47]. But in real-world practice, about 10% of patients report muscle pain that stops them from taking the drug [41, 48], and the PRIMO registry found 10.5% of high-dose statin users had muscle symptoms [41].
The 2025 Korean cohort study comparing high-intensity statin monotherapy to lower-intensity statin plus ezetimibe is worth attention. It found that the combination reduced heart attacks by 36% in primary prevention and 27% in secondary prevention, with fewer liver and muscle problems [2]. That suggests the dose matters: the benefit may come from the lipid lowering, not from the specific drug, and lower doses cause fewer side effects.
| Outcome | Statin vs placebo (primary prevention) | Number needed to treat (NNT) |
|---|---|---|
| All-cause mortality | 14% relative reduction | 89 over ~4 years [19] |
| Major cardiovascular events | 25% relative reduction | 35 over ~4 years [1] |
| Stroke | 16% relative reduction | 174 over ~4 years [19] |
| New-onset diabetes | 9% relative increase | 255 over ~4 years [36] |
| Muscle symptoms | ~10% absolute in practice | 10 per 100 users [41] |
The trials that show the biggest benefit were run in people with established heart disease or very high risk. For a healthy person with no heart disease and a 10-year risk under 10%, the absolute benefit is small enough that the diabetes risk and muscle symptoms can cancel it out. The 2022 NHANES study found a U-shaped relationship between non-HDL cholesterol and mortality, with the lowest risk at about 144 mg/dL, meaning that pushing cholesterol very low may actually increase death risk [25].
My call: for someone who already had a heart attack or stroke, the benefit clearly outweighs the harm. For a healthy person with no heart disease and moderate cholesterol, the benefit is small and the side effects are real. The evidence does not support mass prescribing to healthy people, and the diabetes risk is understated in the marketing. Confidence: moderate for secondary prevention, low for primary prevention in low-risk people.
Sources used 10
-
Primary Prevention of Major Cardiovascular and Cerebrovascular Events with Statins in Diabetic Patients
This meta-analysis evaluates the efficacy of statins in preventing major cardiovascular and cerebrovascular events in diabetic patients, finding a significant 25% risk reduction in such events with statin treatment.
DOI: 10.2165/11638240-000000000-00000 -
Comparative Efficacy of Initial Statin and Ezetimibe Combination versus Statin Monotherapy on Cardiovascular Outcomes in Diabetes Mellitus: A Nationwide Cohort Study
In adults with diabetes, initiating a statin–ezetimibe combination with a lower-intensity statin reduces major adverse cardiovascular events and myocardial infarction compared with high-intensity statin monotherapy, while lowering liver- and diabetes-related hospitalizations in …
DOI: 10.4093/dmj.2024.0482 -
Review: Statins prevent stroke and reduce mortality
This meta-analysis demonstrates that statins significantly reduce all-cause mortality and the incidence of all strokes in adults compared to placebo or no treatment.
DOI: 10.7326/0003-4819-149-2-200807150-02007 -
Statins for the primary prevention of cardiovascular disease
This systematic review assesses the effects of statins for the primary prevention of cardiovascular disease, finding significant reductions in all-cause mortality and major cardiovascular events without an increase in serious adverse effects.
DOI: 10.1002/14651858.cd004816.pub5 -
U-Shaped Relationship of Non-HDL Cholesterol With All-Cause and Cardiovascular Mortality in Men Without Statin Therapy
Non-HDL-C demonstrated a U-shaped relationship with all-cause and cardiovascular mortality in 12,574 US men without statin therapy, with lowest mortality risk at approximately 142-144 mg/dl.
DOI: 10.3389/fcvm.2022.903481 -
Statin use and risk of new-onset diabetes: A meta-analysis of observational studies
This study systematically synthesizes observational evidence to quantify the association between statin use and incident diabetes, finding a ~1.44-fold increased risk with statins overall (notably rosuvastatin and atorvastatin), but with substantial heterogeneity and potential b…
DOI: 10.1016/j.numecd.2017.03.001 -
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
This meta-analysis investigates the relationship between statin therapy and the risk of developing diabetes, finding a slight increase in diabetes risk associated with statin use, particularly in older populations, while emphasizing that the cardiovascular benefits of statins ou…
DOI: 10.1016/s0140-6736(09)61965-6 -
Statin Intolerance From a Clinician’s Perspective
This paper discusses the incidence, mechanisms, and management of statin intolerance from a clinician's perspective, emphasizing the complexities of statin-associated muscle symptoms.
DOI: 10.1177/0003319715587416 -
Statin-induced muscle symptoms
Nocebo effects largely explain statin associated muscle symptoms, and individualized information and management enable most patients to resume or continue statin therapy with fewer or no adverse symptoms.
DOI: 10.61409/v03250169 -
Clinical features related to statin‐associated muscle symptoms
A retrospective, multicenter study identifies clinical factors associated with statin-associated muscle symptoms (SAMS) in statin-intolerant versus statin-tolerant patients, highlighting elevated creatine kinase, family history of heart disease, obesity, hypertension, smoking, a…
DOI: 10.1002/mus.26397